Some limitations were present in this study: First, the number of patients incorporated in the univariate and multivariate Cox analyses patients were reduced as many patients had missing integrated data on all variables; second, only a small number of healthy samples were used as controls, so additional studies are needed to balance sample size; and lastly, laboratory studies should be carried out to elucidate the precise mechanisms of COPB2 overexpression in human glioma and clarify its relationship with poor prognosis and immunomodulation. The gene discussed is COPB2; the disease is central nervous system cancer.